Market revenue in 2023 | USD 2,148.8 million |
Market revenue in 2030 | USD 2,803.5 million |
Growth rate | 3.9% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.44% in 2023. Horizon Databook has segmented the U.S. point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. leads the point-of-care molecular diagnostics market due to the local presence of leading players, such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
Furthermore, according to the American Cancer Society, in 2022, around 1,918,030 new cases of cancer and about 609,360 cancer deaths were anticipated in the U.S. alone. These factors are expected to contribute to the continued dominance of the U.S.
In addition, the regulatory & reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, the FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests while ensuring that the data produced by these tests are accurate & reliable.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account